NDA 021624 · Mylan Institutional
Methadone Hydrochloride
Methadone Hydrochloride · Injection
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1947
Aug 13, 1947
Approved uses
1
Original approval plus efficacy supplements
Registered trials
340
70 Phase 3, 35 recruiting
FAERS reports
43,045
37,168 serious, 13,745 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF METHADONE HYDROCHLORIDE INJECTION Addiction, Abuse, and Misuse Because the use of Methadone Hydrochloride Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions (see WARNINGS ). Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Methadone Hydrochloride Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Methadone Hydrochloride Injection are essential (see WARNINGS ). Neonatal Opioid Withdrawal Syndrome (NOWS) Neonatal opioid withdrawal syndrome (NOWS) is...
What it is approved for
From the label in effect Dec 31, 2025.
INDICATIONS AND USAGE 1. Methadone Hydrochloride Injection is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration (see WARNINGS ), and persist over the course of therapy, reserve opioid analgesics, including Methadone Hydrochloride Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. • Methadone Hydrochloride Injection is not indicated as an as-needed (prn) analgesic. 2. For use in temporary treatment of opioid dependence in patients unable to take oral medication. Limitations of Use • Injectable methadone products are not approved for the outpatient treatment of opioid dependence. In this patient population, parenteral methadone is to be used only for patients unable to take oral medication, such as hospitalized patients. Conditions for Distribution and Use of Methadone Products for the Treatment of Opioid Addiction Code of Federal Regulations, Title 42, Sec 8. Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority. Certified treatment programs shall dispense and use methadone in oral form only and according to the treatment requirements stipulated in the...
Mechanism: Mechanism of Action Methadone hydrochloride is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 13, 1947 Original approval
1 products under this application
- METHADONE HYDROCHLORIDE · METHADONE HYDROCHLORIDE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Methadone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Combined Therapy of Methadone and DextromethrophanPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT01189097 · 1,500 participants (planned) · Start Apr 2008 · Primary completion Mar 2011
Drug: Dextromethorphan; Dextromethorphan · For: Opioid Abuse
Sites: Tainan, Taiwan
- Starting Treatment With Agonist Replacement Therapies (START)Pivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00315341 · 1,269 participants · Start Apr 2006 · Primary completion Aug 2010
Drug: Buprenorphine/naloxone; Methadone · For: Opiate-related Disorders
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 9 sites in all
- The German Project of Heroin Assisted Treatment of Opiate Dependent PatientsPivotal-lookingCompleted
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00268814 · 1,015 participants · Start Mar 2002 · Primary completion Dec 2003
Drug: Diacetylmorphine; Methadone · For: Opioid Dependence
Sites: Karlsruhe, Germany; Munich, Germany; Hamburg, Germany · 7 sites in all
- Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)Pivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03726268 · 907 participants · Start Nov 29, 2018 · Primary completion Jul 30, 2023
Drug: Methadone; Fentanyl and 3 more · For: Opioid Use; Pain, Postoperative
Sites: Durham, North Carolina
- Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.Pivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT06323824 · 600 participants (planned) · Start Jun 4, 2024 · Primary completion Dec 2028
Drug: Methadone; Buprenorphine (BUP) · For: Opioid Use Disorder
Sites: Oakland, California; San Francisco, California; Denver, Colorado · 6 sites in all
- Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After DetoxificationPivotal-lookingCompleted
Shanghai Mental Health CenterAcademic, hospital or other
NCT01580163 · 554 participants · Start Sep 2009 · Primary completion Aug 2013
Drug: JITAI Combined with psychological intervention; Methadone and 1 more · For: Heroin Addiction
Sites: Beijing, China; Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence5,670
- toxicity to various agents5,414
- drug abuse4,962
- overdose3,906
- pain3,705
- death3,637
- drug withdrawal syndrome2,390
- emotional distress2,388
- drug ineffective1,791
- foetal exposure during pregnancy1,694
- drug interaction1,684
- nausea1,655
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 85 |
| 2005 | 290 |
| 2006 | 202 |
| 2007 | 83 |
| 2008 | 76 |
| 2009 | 498 |
| 2010 | 833 |
| 2011 | 699 |
| 2012 | 898 |
| 2013 | 1,896 |
| 2014 | 2,163 |
| 2015 | 2,721 |
| 2016 | 2,142 |
| 2017 | 2,404 |
| 2018 | 3,491 |
| 2019 | 2,699 |
| 2020 | 4,483 |
| 2021 | 5,417 |
| 2022 | 3,379 |
| 2023 | 2,750 |
| 2024 | 2,412 |
| 2025 | 2,050 |
| 2026 | 1,373 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L, Clark B, Macpherson G, et al. · Lancet Psychiatry 2023 · Meta-Analysis, Systematic Review
- Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis.
D'Souza RS, Gurrieri C, Johnson RL, et al. · Pain 2020 · Meta-Analysis, Systematic Review
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. · BMJ 2017 · Meta-Analysis, Systematic Review
- Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis.
Ray LA, Meredith LR, Kiluk BD, et al. · JAMA Netw Open 2020 · Meta-Analysis, Research Support, N.I.H., Extramural
- Shifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis.
Imkamp MSV, Theunissen M, Viechtbauer W, et al. · J Pain Symptom Manage 2024 · Systematic Review, Network Meta-Analysis
- Buprenorphine Compared with Methadone in Pregnancy: A Systematic Review and Meta-Analysis.
Kinsella M, Halliday LOE, Shaw M, et al. · Subst Use Misuse 2022 · Meta-Analysis, Systematic Review
Sponsor: Mylan Institutional
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.